AnaptysBio, Inc.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novo Nordisk, IMMvention Collaboration

Actuate Therapeutics, Inc. grossed $22.4m from its initial public offering of 2.8 million shares priced at $8 each in the 15th biopharmaceutical company IPO in the US in 2024. It was not the smallest

The US FDA’s approval of BeiGene, Ltd. ’s PD-1 inhibitor Tevimbra (tislelizumab-jsgr) removes one of the last novel agent applications delayed by COVID-19 from the agency’s review queue. The 13 March